Aeterna Zentaris Stock Forecast, Price & News

Aeterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AEZS stock has increased by 13.2% and is now trading at $0.7690.
View which stocks have been most impacted by COVID-19.

Wall Street analysts have given Aeterna Zentaris a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aeterna Zentaris wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

1,448 employees have rated Aeterna Zentaris CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Aeterna Zentaris' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Aeterna Zentaris is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Aeterna Zentaris.

Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $0.13 million during the quarter. Aeterna Zentaris had a negative return on equity of 125.54% and a negative net margin of 369.10%.
View Aeterna Zentaris' earnings history.

Aeterna Zentaris saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,890,000 shares, an increase of 28.6% from the December 15th total of 1,470,000 shares. Based on an average daily trading volume, of 2,130,000 shares, the short-interest ratio is currently 0.9 days. Currently, 3.2% of the company's shares are sold short.
View Aeterna Zentaris' Short Interest.

Some companies that are related to Aeterna Zentaris include Novan (NOVN), Aquestive Therapeutics (AQST), 9 Meters Biopharma (NMTR), GlycoMimetics (GLYC), Theratechnologies (THERF), Taiwan Liposome (TLC), Theratechnologies (THTX), scPharmaceuticals (SCPH), Clearside Biomedical (CLSD), Sierra Oncology (SRRA), Kindred Biosciences (KIN), AcelRx Pharmaceuticals (ACRX), Eyenovia (EYEN), DiaMedica Therapeutics (DMAC) and Ovid Therapeutics (OVID).
View all of AEZS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG).

Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AEZS stock can currently be purchased for approximately $0.77.

Aeterna Zentaris has a market capitalization of $48.20 million and generates $530,000.00 in revenue each year.

The official website for Aeterna Zentaris is www.zentaris.com.

Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 49-6942-6020 or via email at [email protected]